HONG KONG SAR - Media OutReach- 5 February 2021 - JBM (Healthcare)Limited ("JBM Healthcare" or "Company", together with itssubsidiaries, the "Group"), a HongKong-based company that markets and distributes branded healthcare productsacross Greater China, Southeast Asia and certain other countries, started tradingtoday on the Main Board of The Stock Exchange of Hong Kong Limited ("SEHK")under stock code 2161.

JBM Healthcare's diversified brand portfolio comprises a total of 20 principal brands, including 11 third-party brands and 9 own brands.

As a subsidiary of JacobsonPharma Corporation Limited ("Jacobson Pharma"; Stock Code: 2633), JBMHealthcare is a unique field player with drug expertise and ethical heritagethat prioritises product efficacy and quality to meet consumers' healthcareneeds. As a leading healthcare brand operator in Hong Kong, the Group carried atotal of 20 principal brands, including 11 third-party brands and 9 own brands coveringboth OTC proprietary medicines and OTC proprietary Chinese medicines. Upon completion of the public listing, JacobsonPharma continues to indirectly hold over 50% equity interest in JBM Healthcareand JBM Healthcare remains as a subsidiary of Jacobson Pharma.

Further to the successful listing, the Group will aim atexpanding its product offerings and deepening product penetration in Chinathrough cross-border e-commerce initiatives as a result of the rapid growth ofthe PRC cross-border e-commerce market, as well as the rising demand foroverseas healthcare products along with an increasingly structured and formalizedcross-border e-commerce channel in the PRC market. Simultaneously, the Group willalso further expand its portfolio through organic growth and mergers andacquisitions to maintain its competitive position and ensure its future growthand success.

Leveraging the Group'sestablished local business relationships and networks, JBM Healthcare targetsto develop a branded healthcare product sourcing and distribution platform inAsia through the integration of its regional resources and foothold, strengtheningand expanding its geographical reach in Southeast Asia. In addition, backed by itsextensive market base in Hong Kong, the Group is well poised to unleash thesales and distribution potential of its Chinese medicine practitioner network.

The net proceeds from the Public Offer amounted to approximately HK$10.6million. The Group will allocate 47.2% of the proceeds to fund portfolio development and brand management of proprietary Chinesemedicines; while 43.4% will be used to pay for the obtaining of additionaldistribution rights from third-party brand owners, as part of the strategy togrow its third-party brand product portfolio. The remaining 9.4 % will be usedto supplement working capital and for general corporate purposes.

About JBM (Healthcare) Limited (健倍苗苗（保健）有限公司；Stock Code: 2161)

JBM Healthcare is a HongKong-based company that markets anddistributes branded healthcare products with a product footprint acrossGreater China, Southeast Asia and certain other countries. As a leadinghealthcare brand operator in Hong Kong, JBM Healthcare carries a portfolio of awide range of branded healthcare products, comprising branded medicines, healthand wellness products and proprietary Chinese medicines. Formore details about JBM Healthcare, please visit: www.jbmhealthcare.com.hk